Neuroprotection is defined as preventing, halting or slowing down the rate of nerve cell death. The purpose of this study is to determine if Rilutek will have the same effect in persons with Parkinson's disease. As with any medication, there is always a potential for risks. If you qualify for this study, the risks will be explained in detail. Individuals meeting the broad criteria for the study will be further evaluated at a study site.
Evaluation includes medical history, physical examination, and laboratory tests.
Further Information View clinical trial locations in the United States . This site intended for use by U.S. residents only.